腹膜転移を伴う胃がんの治療のための、パクリタキセルおよびラムシルマブとの併用によるNab-パクリタキセル PIPAC
腹膜転移を伴う胃がんの二次療法と併用したNab-パクリタキセル PIPAC(加圧腹腔内エアロゾル化化学療法)の第1相試験
This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of nab-paclitaxel PIPAC when given in combination with standard-of-care second-line systemic therapy (paclitaxel, ramucirumab).
II. To assess the safety and tolerability of nab-paclitaxel PIPAC plus systemic paclitaxel and ramucirumab, and accompanying dose modification plan, by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration.
SECONDARY OBJECTIVES:
I. To evaluate the anti-tumor activity of nab-paclitaxel when given in combination with standard-of-care second-line systemic therapy (paclitaxel, ramucirumab), as assessed by:
Ia. Response Evaluation Criteria in Solid Tumors (RECIST), if available, version 1.1 via computed tomography (CT) scan at baseline and every 8 weeks until disease progression; Ib. Peritoneal Regression Grading Score (PRGS) via biopsy at each PIPAC cycle (both pre-PIPAC and post-PIPAC peritoneal samples will be obtained); Ic. Peritoneal Carcinomatosis Index (PCI) at the time of laparoscopy; and Id. Overall survival (OS) and progression-free survival (PFS) estimates at 6-months, 1-year and 2-years.
II. To estimate the PIPAC technical failure rate. III. To characterize and evaluate peritoneal tumor associated complications. IV. To characterize and evaluate post-operative surgical complications by Clavien-Dindo classification evaluated at 30 days after each PIPAC technical failure rate.
V. To evaluate patient-reported health state/quality of life and symptoms before treatment and at 6, 12, 18, and 24 weeks/off study, as measured by the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) and MD Anderson Symptom Inventory (MDASI).
EXPLORATORY OBJECTIVES:
I. Characterize the peritoneal tumor and immune tumor microenvironment changes in response to therapy.
II. Evaluate the pharmacokinetics of nab-paclitaxel PIPAC. III. Evaluate patients' quality of life during nab-paclitaxel PIPAC plus systemic therapy.
OUTLINE: This is a dose-escalation study of nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab followed by a dose-expansion study.
Patients receive nab-paclitaxel PIPAC intraperitoneally (IP) over 40 minutes on day 1 and standard of care (SOC) paclitaxel intravenously (IV) over 60 minutes on days 15, 22, 29, 43, and 50 and ramucirumab IV over 30-60 minutes on days 15, 29 and 43 of each cycle. Cycles repeat every 8 weeks (56 days) for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may then continue SOC paclitaxel IV on days 1, 8, and 15 and ramucirumab IV on days 1 and 15 of each cycle per physician as deemed appropriate. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, tumor biopsy, and CT or magnetic resonance imaging (MRI) throughout the study.
After completion of study treatment, patients are followed up at 4 weeks, then every 3 months for year 1 followed by every 6 months until progression or initiation of a new systemic anti-cancer therapy or death, whichever occurs first.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope Medical Center
-
主任研究者:
- Yanghee Woo
-
コンタクト:
- Yanghee Woo
- 電話番号:626-218-0220
- メール:yhwoo@coh.org
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must have failed first-line systemic therapy (fluorouracil, leucovorin calcium, oxaliplatin [FOLFOX] with or without immunotherapy, or other fluoropyrimidine and platinum-based therapy)
- Prior immunotherapy allowed
- Up to 4 cycles of second-line therapy allowed if no progression is documented
-
Documented informed consent of the participant and/or legally authorized representative
- Assent, when appropriate, will be obtained per institutional guidelines
-
Agreement to allow the use of archival tissue from diagnostic tumor biopsies
- If unavailable, exceptions may be granted with study principal investigator (PI) approval
-
Age: ≥ 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Histologically or cytologically confirmed gastric adenocarcinoma
-
Visible peritoneal metastatic disease on cross-sectional imaging or diagnostic laparoscopy (does not have to be measurable by RECIST 1.1)
-
Fully recovered from acute toxic effects (except alopecia, hearing loss, or non-clinically significant laboratory abnormalities) ≤ grade 1 of prior anti-cancer therapy
-
The patient's urinary protein is ≤ 1+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥ 2+, then a 24-hour urine must be collected and must demonstrate < 1000mg protein in 24 hours
-
Complete medical history and physical exam (within 28 days prior to day 1 of protocol therapy)
-
Absolute neutrophil count (ANC) ≥ 1,500/mcL (within 28 days prior to day 1 of protocol therapy)
-
Platelets ≥ 100,000/mcL (within 28 days prior to day 1 of protocol therapy)
-
Hemoglobin ≥ 8 g/dL (within 28 days prior to day 1 of protocol therapy)
-
Serum albumin ≥ 2.8 g/dL (within 28 days prior to day 1 of protocol therapy)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease, then direct bilirubin < 1.5 mg/dL) (within 28 days prior to day 1 of protocol therapy)
-
Aspartate aminotransferase (AST) ≤ 5 x ULN (within 28 days prior to day 1 of protocol therapy)
-
Alanine aminotransferase (ALT) ≤ 5 x ULN (within 28 days prior to day 1 of protocol therapy)
-
International normalized ratio (INR) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)
-
Prothrombin time (PT) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)
-
Partial thromboplastin time (PTT) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)
-
Calculated creatinine clearance of ≥ 45 mL/min per 24 hour urine test or the Cockcroft-Gault formula (within 28 days prior to day 1 of protocol therapy)
-
Seronegative for HIV antigen (Ag)/antibody (Ab) combo (within 28 days prior to day 1 of protocol therapy)
- If seropositive, patient may be eligible if they are stable on antiretroviral therapy, have a CD4 T cell count ≥ 200/µL, and have an undetectable viral load
-
Documented virology status of hepatitis, confirmed by hepatitis B virus (HBV) and hepatitis C virus (HCV) tests (within 28 days prior to day 1 of protocol therapy)
- For patients with active HBV, HBV deoxyribonucleic acid (DNA) < 500 IU/mL during screening, initiation of anti-HBV treatment at least 14 days prior to day 1 of cycle 1, and willingness to continue anti-HBV treatment during the study (per standard of care)
- If seropositive for HCV, nucleic acid quantification must be performed. Viral load must be undetectable
-
WOMEN OF CHILDBEARING POTENTIAL (WOCBP): Negative urine or serum pregnancy test (within 28 days prior to day 1 of protocol therapy)
- If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Agreement by females and males of childbearing potential to use an effective method of birth control (e.g., licensed hormonal/barrier methods or surgery intended to prevent pregnancy [or with a side effect of pregnancy prevention]) or abstain from heterosexual activity for the course of the study through at least 14 months after the last dose of protocol therapy.
- Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
Exclusion Criteria:
-
Intolerance to taxanes
-
Bowel obstruction requiring exclusive total parenteral nutrition
-
Any history of, or current, brain or subdural metastases
-
Life expectancy < 3 months
-
Treatment with therapeutic oral or IV antibiotics within 14 days prior to day 1 cycle 1 of treatment
- Patients receiving prophylactic antibiotics are eligible, provided the signs of active infection have resolved
-
Any prior malignancy except adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for two years
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents (taxanes, etc.)
-
Clinically significant uncontrolled illness such as uncontrolled hypertension (HTN)
-
History of arterial thromboembolic events such as myocardial infarction (MI), cerebrovascular accident (CVA)
-
History of gastrointestinal (GI) perforation
-
FEMALES ONLY: Pregnant or breastfeeding
-
Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
-
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (nab-paclitaxel PIPAC, paclitaxel, ramucirumab)
Patients receive nab-paclitaxel PIPAC IP over 40 minutes on day 1 and SOC paclitaxel IV over 60 minutes on days 15, 22, 29, 43, and 50 and ramucirumab IV over 30-60 minutes on days 15, 29 and 43 of each cycle. Cycles repeat every 8 weeks (56 days) for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may then continue SOC paclitaxel IV on days 1, 8, and 15 and ramucirumab IV on days 1 and 15 of each cycle per physician as deemed appropriate. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, tumor biopsy, and CT or MRI throughout the study. |
Given IV
他の名前:
Undergo blood sample collection
他の名前:
Undergo tumor biopsy
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Ancillary studies Given IV
他の名前:
Given PIPAC Given IP
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dose-limiting toxicity (DLT)
時間枠:Up to 6 weeks after the first pressurized intraperitoneal aerosolized chemotherapy (PIPAC) treatment
|
Will be evaluated and graded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Toxicities will be summarized by type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment, and reversibility or outcome. Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated. |
Up to 6 weeks after the first pressurized intraperitoneal aerosolized chemotherapy (PIPAC) treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of treatment-related adverse events (AEs)
時間枠:Up to 4 weeks after last dose of nab-paclitaxel
|
Will be evaluated and graded based on NCI CTCAE v 5.0. The number and percent of patients with AEs will be tabulated by system organ class and preferred term using the Medical Dictionary for Regulatory Activities preferred term dictionary. The tabulations will be generated so that the number and percent of patients with events in each severity, relatedness, and serious category can be obtained for each preferred term. Listings and narratives will be provided for deaths on study, serious AEs, DLTs, and events leading to discontinuation of treatment. |
Up to 4 weeks after last dose of nab-paclitaxel
|
|
Incidence of post-operative surgical complications
時間枠:At 4 weeks post-PIPAC procedure
|
Will be evaluated using Clavien-Dindo classification. Results will be strictly descriptive in nature. |
At 4 weeks post-PIPAC procedure
|
|
Objective response rate (ORR)
時間枠:Up to 2 years
|
Will be evaluated according to Response Evaluation Criteria in Solid Tumors v 1.1. ORR will be defined as the percentage of evaluable patients who have achieved complete response (CR), partial response (PR), or stable disease (SD). Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated. |
Up to 2 years
|
|
Peritoneal Carcinomatosis Index (PCI)
時間枠:At time of laparoscopy
|
PCI will be defined as the percentage of evaluable patients who have achieved CR, PR, or SD. Confidence intervals for the true success proportion will be calculated according to the approach of Clopper and Pearson |
At time of laparoscopy
|
|
Peritoneal Regression Grading Score (PRGS)
時間枠:At baseline and post-PIPAC, assessed up to 2 years
|
PRGS will be defined as the percentage of evaluable patients who have achieved a decrease in the PRGS over successive biopsies. Confidence intervals for the true success proportion will be calculated according to the approach of Clopper and Pearson |
At baseline and post-PIPAC, assessed up to 2 years
|
|
Progression-free survival (PFS)
時間枠:From first PIPAC to progression of disease, assessed up to 2 years
|
PFS will be estimated using the Kaplan-Meier estimator and 95% confidence intervals will be calculated using the logit transformation and the Greenwood variance estimate. |
From first PIPAC to progression of disease, assessed up to 2 years
|
|
Overall survival (OS)
時間枠:From initiation of treatment to death or last contact, whichever occurs first up to 2 years
|
OS will be estimated using the Kaplan-Meier estimator and 95% confidence intervals will be calculated using the logit transformation and the Greenwood variance estimate. |
From initiation of treatment to death or last contact, whichever occurs first up to 2 years
|
|
PIPAC technical failure rate
時間枠:Up to 2 years
|
The technical failure rate will be calculated. The device malfunction rate will also be calculated. Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated. |
Up to 2 years
|
|
Patient-reported health status and quality of life
時間枠:At baseline and at 6, 12, 18 and 24 weeks off study
|
Will be measured using the European Quality of Life Five Dimension Five Level Scale and will be summarized with descriptive statistics. |
At baseline and at 6, 12, 18 and 24 weeks off study
|
|
Patient-reported symptoms
時間枠:At baseline and at 6, 12, 18 and 24 weeks off study
|
Will be measured using the MD Anderson Symptom Inventory and will be summarized with descriptive statistics. |
At baseline and at 6, 12, 18 and 24 weeks off study
|
|
Time to peritoneal tumor associated complications
時間枠:Up to 2 years
|
Will be estimated using the Kaplan-Meier estimator and 95% confidence intervals will be calculated using the logit transformation and the Greenwood variance estimate. |
Up to 2 years
|
|
Functional status
時間枠:Up to 1 year
|
Will be measured by the number of daily steps before and after treatments. |
Up to 1 year
|
協力者と研究者
捜査官
- 主任研究者:Yanghee Woo、City of Hope Medical Center
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 外科的処置、手術
- 細胞学的技術
- 細胞診断
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- タキソイド
- シクロデカン
- Diterpenes
- ヘルスケアの経済学と組織
- 診断技術、外科的
- 化学技術、分析
- スペクトル分析
- アルブミン
- 経済
- アルブミン結合パクリタキセル
- ラムシルマブ
- パクリタキセル
- 生検
- 標本処理
- 磁気共鳴分光法
- 130 nmアルブミンに縛られたパクリタキセル
- 税金
その他の研究ID番号
- 24445
- P30CA033572 (米国 NIH グラント/契約)
- 24445 (その他の識別子:City of Hope Medical Center)
- NCI-2024-08883 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。